Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone612-379-8854
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$714.01 million
Profitability
Miscellaneous
Employees2,250
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Tuesday, February 4th. Investors of record on Friday, February 14th will be given a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 annualized dividend and a yield of 0.61%. The ex-dividend date is Thursday, February 13th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings data on Tuesday, February, 4th. The biotechnology company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.13 by $0.05. The biotechnology company earned $184.93 million during the quarter, compared to analyst estimates of $191.34 million. BIO-TECHNE had a return on equity of 12.45% and a net margin of 26.20%. The firm's quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.06 earnings per share. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
8 Wall Street analysts have issued 12 month price objectives for BIO-TECHNE's shares. Their forecasts range from $225.00 to $270.00. On average, they expect BIO-TECHNE's stock price to reach $238.33 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Has BIO-TECHNE been receiving favorable news coverage?
Headlines about TECH stock have been trending extremely negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIO-TECHNE earned a news impact score of -4.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for BIO-TECHNE.
Are investors shorting BIO-TECHNE?
BIO-TECHNE saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 485,700 shares, an increase of 16.2% from the January 15th total of 418,000 shares. Based on an average daily trading volume, of 124,100 shares, the short-interest ratio is currently 3.9 days. Approximately 1.3% of the shares of the company are short sold. View BIO-TECHNE's Current Options Chain.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).
What other stocks do shareholders of BIO-TECHNE own?
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
- Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
- Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
- Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
- Mr. Gerry Andros, VP of Sales and Marketing
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bamco Inc. NY (4.00%), Janus Henderson Group PLC (3.17%), Mairs & Power INC (2.62%), Jackson Square Partners LLC (2.56%), State Street Corp (2.33%) and Champlain Investment Partners LLC (2.26%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.
Which institutional investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, First Trust Advisors LP, Janus Henderson Group PLC, Renaissance Technologies LLC, Schroder Investment Management Group, AQR Capital Management LLC, Bamco Inc. NY and Mairs & Power INC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.
Which institutional investors are buying BIO-TECHNE stock?
TECH stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Jackson Square Partners LLC, Candriam Luxembourg S.C.A., Candriam Luxembourg S.C.A., Geode Capital Management LLC, Champlain Investment Partners LLC, Man Group plc and Thrivent Financial for Lutherans. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $208.87.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $8.01 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.
What is BIO-TECHNE's official website?
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
